What I would do is close to what a certain fairly mainstream set of health care reformers would like to do. It would involve reducing much spending in the last three months of life when a terminal condition exists, it would involve taking age into account in allocating donated organs. It would involve drug companies showing that a proposed new drug is more effective (or otherwise significantly superior to) existing medications, not just that it is effective. Although this is not an idea I have seen elsewhere, I might also take an “end-to-end” approach to medical research, wanting to see a sort of “business plan” that shows enough benefit to enough patients to justify costs. Any life extension treatments would be considered using the same set of criteria. Giving frail, confused 85-year-olds another ten years of the same kind of life would not qualify as a positive outcome.
What I would do is close to what a certain fairly mainstream set of health care reformers would like to do. It would involve reducing much spending in the last three months of life when a terminal condition exists, it would involve taking age into account in allocating donated organs. It would involve drug companies showing that a proposed new drug is more effective (or otherwise significantly superior to) existing medications, not just that it is effective. Although this is not an idea I have seen elsewhere, I might also take an “end-to-end” approach to medical research, wanting to see a sort of “business plan” that shows enough benefit to enough patients to justify costs. Any life extension treatments would be considered using the same set of criteria. Giving frail, confused 85-year-olds another ten years of the same kind of life would not qualify as a positive outcome.